Patent ID: 6066321
Filing Date: 2000-05-23
Classification: A61K,A61P,C07K

Abstract:
A method for antagonizing VAP-1-mediated binding of endothelial cells to lymphocytes in a patient, said method comprising providing, to said patient, an effective amount of a composition that inhibits the VAP-1-mediated lymphocyte-endothelial cell adhesion reaction, said composition comprising a pharmaceutically acceptable carrier and a compound that inhibits the VAP-1-mediated lymphocyte-endothelial cell adhesion reaction, wherein said compound is selected from the group consisting of a VAP-1 specific antibody, and an antigen binding fragment of said VAP-1 specific antibody wherein said VAP-1 specificant wherein said VAP-1 specific antibody binds VAP-1, wherein said VAP-1(a) has a molecular weight of about 170 kD when resolved under conditions selected from reduced or non-reduced sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE); and specifically binds monoclonal antibody 1B2 (DSM ACC2041); or(b) has a molecular weight of about 90 kD when immunopurified with monoclonal antibody 1B2 (DSM ACC2041) and resolved under reducing conditions by sodium dodecylsulfate polyacrylamide gel electrophoresis; and specifically binds monoclonal antibody 1B2 (DSM ACC2041), wherein said 90 kD VAP-1 protein is not identical to a cross-reactive mouse cyclophilin C associated protein.